farnesol has been researched along with Neoplasms in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.00) | 18.2507 |
| 2000's | 5 (25.00) | 29.6817 |
| 2010's | 14 (70.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arellano, ML; Boggon, TJ; Brat, DJ; Chen, GZ; Chen, J; Chen, PR; DeBerardinis, RJ; Elf, S; Fan, J; Gu, TL; He, C; Hitosugi, T; Hurwitz, SJ; Ji, Q; Jiang, L; Kang, HB; Kang, S; Khoury, HJ; Khuri, FR; Lee, BH; Lei, Q; Li, Y; Lin, R; Lonial, S; Mao, H; Mitsche, M; Seo, JH; Shan, C; Sudderth, J; Tucker, M; Wang, D; Wu, S; Xie, J; Ye, K; Zhang, L; Zhang, S; Zhou, L | 1 |
| Fujisaka, Y; Furuse, J; Iwasa, T; Kitamura, H; Kurata, T; Nagashima, F; Nakagawa, K; Naruge, D; Okano, N; Shimizu, T | 1 |
| Ahn, KS; Arfuso, F; Fan, L; Hwang, ST; Jung, YY; Sethi, G | 1 |
| Arora, N; Gupta, P; Poluri, KM; Pruthi, V; Sharma, M | 1 |
| Morris, AJ; Onono, F; Spielmann, HP; Subramanian, KL; Subramanian, T; Sunkara, M | 1 |
| Efferth, T; Kuete, V | 1 |
| Chen, L; Huang, Z; Ling, Y; Wang, X; Wang, Z; Zhang, W; Zhang, Y; Zhu, H | 1 |
| Elad-Sfadia, G; Haklai, R; Kloog, Y; Mor, A | 1 |
| Chen, L; Dai, H; Li, X; Ling, Y; Wang, X; Wang, Z; Zhang, W; Zhang, Y | 1 |
| Kloog, Y; Pinkas-Kramarski, R; Schmukler, E; Schokoroy, ST; Wolfson, E | 1 |
| Bauer, V; Goldberg, L; Haklai, R; Heiss, A; Kloog, Y | 1 |
| Blair, J; Goldsweig, H; Hong, D; Kurzrock, R; Ng, CS; Rudek, MA; Tsimberidou, AM | 1 |
| Jetten, AM; Joo, JH | 1 |
| Bustinza-Linares, E; Kurzrock, R; Tsimberidou, AM | 1 |
| Alperstein, D; Kloog, Y; Kraitzer, A; Zilberman, M | 1 |
| Fairn, GD; MacDonald, K; McMaster, CR | 1 |
| Blum, R; Elkon, R; Jacob-Hirsch, J; Kloog, Y; Rechavi, G; Shamir, R; Yaari, S; Zundelevich, A | 1 |
| Ehrlich, M; Haklai, R; Kloog, Y; Rotblat, B | 1 |
| kato, J; Kogo, Y | 1 |
| Cox, AD; Kloog, Y | 1 |
9 review(s) available for farnesol and Neoplasms
| Article | Year |
|---|---|
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; Oxidative Stress; Pentose Phosphate Pathway; Phosphogluconate Dehydrogenase; Protein Serine-Threonine Kinases; Ribulosephosphates; Signal Transduction | 2015 |
Potential Anti-Inflammatory and Anti-Cancer Properties of Farnesol.
Topics: Apoptosis; Cyclooxygenase 2; Farnesol; Gene Expression Regulation, Neoplastic; Humans; Inflammation; Neoplasms; Nitric Oxide Synthase Type II; ras Proteins; Tumor Necrosis Factor-alpha | 2018 |
Chemistry and Biology of Farnesol and its Derivatives: Quorum Sensing Molecules with Immense Therapeutic Potential.
Topics: Antifungal Agents; Antineoplastic Agents; Biofilms; Drug Screening Assays, Antitumor; Farnesol; Fungi; Humans; Microbial Sensitivity Tests; Neoplasms; Quorum Sensing | 2018 |
Ras chaperones: new targets for cancer and immunotherapy.
Topics: Animals; Antineoplastic Agents; Farnesol; Humans; Immunotherapy; Molecular Chaperones; Neoplasms; ras Proteins; Salicylates; Signal Transduction | 2013 |
Enhancing FTS (Salirasib) efficiency via combinatorial treatment.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Farnesol; Humans; Neoplasms; Salicylates; Signal Transduction | 2015 |
Molecular mechanisms involved in farnesol-induced apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosomes; Cell Proliferation; Cytidine Diphosphate Choline; Endoplasmic Reticulum; Farnesol; Humans; Hydroxymethylglutaryl CoA Reductases; Mitogen-Activated Protein Kinases; Neoplasms; NF-kappa B; Oxidative Stress; PPAR gamma; Receptors, Cytoplasmic and Nuclear; Signal Transduction; Thyroid Hormone Receptors beta; Unfolded Protein Response | 2010 |
Salirasib in the treatment of pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Membrane; Clinical Trials, Phase I as Topic; Deoxycytidine; Disease-Free Survival; Drug Screening Assays, Antitumor; Farnesol; Farnesyltranstransferase; Galectins; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Middle Aged; Neoplasm Proteins; Neoplasms; Pancreatic Neoplasms; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Salicylates; Signal Transduction | 2010 |
[Malignant tumor and apoptosis].
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Apoptosis; Farnesol; Farnesyltranstransferase; Humans; Neoplasms; ras Proteins; Tumor Suppressor Protein p53 | 1997 |
RAS inhibitors: potential for cancer therapeutics.
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Drug Design; Enzyme Inhibitors; Farnesol; Farnesyltranstransferase; Humans; Neoplasms; ras Proteins; Salicylates | 2000 |
2 trial(s) available for farnesol and Neoplasms
| Article | Year |
|---|---|
An early clinical trial of Salirasib, an oral RAS inhibitor, in Japanese patients with relapsed/refractory solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dose-Response Relationship, Drug; Enzyme Inhibitors; Farnesol; Female; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; ras Proteins; Salicylates | 2018 |
Phase 1 first-in-human clinical study of S-trans,trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Farnesol; Female; Humans; Lymphoma; Male; Middle Aged; Neoplasms; Salicylates; Stereoisomerism | 2010 |
9 other study(ies) available for farnesol and Neoplasms
| Article | Year |
|---|---|
Efficient use of exogenous isoprenols for protein isoprenylation by MDA-MB-231 cells is regulated independently of the mevalonate pathway.
Topics: Antineoplastic Agents; Cell Line, Tumor; Diterpenes; Farnesol; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mevalonic Acid; Mutation; Neoplasms; Polyisoprenyl Phosphates; Protein Prenylation; Tumor Suppressor Protein p53 | 2013 |
Molecular determinants of cancer cell sensitivity and resistance towards the sesquiterpene farnesol.
Topics: Antibiotics, Antineoplastic; ATP-Binding Cassette Transporters; Cell Division; Cell Line, Tumor; Cluster Analysis; Doxorubicin; Drug Resistance, Neoplasm; Farnesol; Genes, erbB-1; Genes, p53; HL-60 Cells; Humans; Microarray Analysis; Neoplasms; Oxazines; RNA, Messenger; Transfection; Xanthenes | 2013 |
Synthesis and biological evaluation of farnesylthiosalicylamides as potential anti-tumor agents.
Topics: Antineoplastic Agents; Apoptosis; Farnesol; Humans; Neoplasms; Salicylates; Signal Transduction | 2014 |
Hybrid molecule from Farnesylthiosalicylic acid-diamine and phenylpropenoic acid as Ras-related signaling inhibitor with potent antitumor activities.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Diamines; Farnesol; Humans; Neoplasms; NF-kappa B; Phenylpropionates; Phosphorylation; ras Proteins; Salicylates; Signal Transduction | 2015 |
New derivatives of farnesylthiosalicylic acid (salirasib) for cancer treatment: farnesylthiosalicylamide inhibits tumor growth in nude mice models.
Topics: Amides; Animals; Antineoplastic Agents; Cell Line, Tumor; Cyclic AMP-Dependent Protein Kinases; Disease Models, Animal; Disease Progression; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Farnesol; Humans; MAP Kinase Signaling System; Mice; Mice, Nude; Molecular Structure; Neoplasms; Oncogene Protein p21(ras); Salicylates; Xenograft Model Antitumor Assays | 2009 |
Mechanisms of antiproliferative drug release from bioresorbable porous structures.
Topics: Antineoplastic Agents; Biocompatible Materials; Drug-Eluting Stents; Farnesol; Humans; Models, Molecular; Neoplasms; Paclitaxel; Polyglactin 910; Porosity; Salicylates; Sirolimus; Solubility | 2013 |
A chemogenomic screen in Saccharomyces cerevisiae uncovers a primary role for the mitochondria in farnesol toxicity and its regulation by the Pkc1 pathway.
Topics: Animals; Cell Death; DNA, Mitochondrial; Drug Resistance, Fungal; Electron Transport; Electron Transport Complex III; Farnesol; Genome, Fungal; Humans; Iron-Sulfur Proteins; MAP Kinase Kinase 1; Mitochondria; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; Neoplasms; Protein Kinase C; Protein Transport; Reactive Oxygen Species; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Signal Transduction | 2007 |
Gene expression signature of human cancer cell lines treated with the ras inhibitor salirasib (S-farnesylthiosalicylic acid).
Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cluster Analysis; Down-Regulation; Farnesol; Gene Expression; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Neoplasms; Promoter Regions, Genetic; ras Proteins; Salicylates; Transcription, Genetic; Up-Regulation | 2007 |
The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancer.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Cells, Cultured; Farnesol; Humans; Mice; Neoplasms; ras Proteins; Salicylates; Signal Transduction | 2008 |